Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28984108 | 0.79 | HRH3 (0.44) | HRH3KCNH2 | |
| SCHEMBL25826613 | 0.79 | ESR1 (0.37) | HRH3ESR1THRATHRBCASR | |
| SCHEMBL13039961 | 0.77 | ESR1 (0.54) | ESR1THRATHRB | |
| SCHEMBL25827944 | 0.76 | HRH3 (0.36) | HRH3KCNH2 | |
| SCHEMBL25827939 | 0.74 | ESR1 (0.40) | HRH3ESR1KCNH2THRATHRB | |
| SCHEMBL18503215 | 0.74 | TDP1 (0.53) | HRH3TDP1L3MBTL1 | |
| SCHEMBL18503192 | 0.74 | TDP1 (0.53) | HRH3TDP1L3MBTL1 | |
| SCHEMBL18503221 | 0.74 | TDP1 (0.53) | HRH3TDP1L3MBTL1 | |
| SCHEMBL18503223 | 0.74 | TDP1 (0.53) | HRH3TDP1L3MBTL1 | |
| SCHEMBL18503188 | 0.74 | TDP1 (0.53) | HRH3TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | HRH3 2453/4885ESR1 1503/4885KCNH2 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.